Amivantamab monotherapy (CHRYSALIS) — 2L EGFR Exon 20 insertion NSCLC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-AMIVANTAMAB |
|---|
| ID | REG-AMIVANTAMAB-MONO-NSCLC-EX20INS |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-CHRYSALIS-PARK-2021 SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
CHRYSALIS: ORR 40%, mPFS 8.3 mo, mOS 22.8 mo in EGFR Ex20ins pretreated. FDA accelerated approval 2021. PAPILLON (1L combo with carbo+pem) is now SoC for treatment-naïve EGFR Ex20ins; mono used 2L+ post-platinum. SC formulation strongly preferred.
Used By
Indication
IND-NSCLC-2L-EGFR-EX20INS-AMIVANTAMAB- IND-NSCLC-2L-EGFR-EX20INS-AMIVANTAMAB